No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist. This phase I/II trial investigated safety, pharmacokinetics (PK) and potential biomarkers of the deacetylase inhibitor (HDAC) resminostat and a combination therapy with resminostat and sorafenib.
Resminostat in combination with sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER Study
GIANNINI, EDOARDO GIOVANNI;
2016-01-01
Abstract
No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist. This phase I/II trial investigated safety, pharmacokinetics (PK) and potential biomarkers of the deacetylase inhibitor (HDAC) resminostat and a combination therapy with resminostat and sorafenib.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
J Hepatol & resminostat.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
953.65 kB
Formato
Adobe PDF
|
953.65 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
